士泽生物医药 Alternatives & Competitors
12 companies similar to 士泽生物医药 — 病人第一 ,刀锋第二 ,股东第三
Companies similar to 士泽生物医药
BlueRock Therapeutics
Striving to transform the treatment of disease by harnessing the power of cell therapy
CRISPR Therapeutics
Gene-based medicines for patients with serious diseases
KeifeRx
KeifeRx is a biopharmaceutical company finding disease-modifying treatments for neurodegen...
BIORCHESTRA Co., Ltd.
We develop novel RNA-based therapeutics that will be able to bring about a paradigm shift...
Rival Readout
Competing with 士泽生物医药? We do this properly.
10 rivals, 90 days of dated moves, ranked by what matters and sourced, in 7 business days.
Ultragenyx
Going Beyond Every Day
Cullinan Therapeutics
Science That Moves
Heartseed Inc.
Clinical-stage biotech company developing iPSC-derived highly purified ventricular cardiom...
SyneuRx International (Taiwan) Corp.
Developing new classes of drugs for COVID-19 and multiple major central nervous system dis...
Adendra Therapeutics
Translating dendritic cell biology into new therapies for cancer and autoimmunity.
Jasper Therapeutics
Jasper is a biotechnology company focused on targeting mast cells and stem cells to treat...
Avidity Biosciences, Inc.
At Avidity, we are developing a new class of oligonucleotide-based therapies.
Cellcolabs
Cellcolabs mission is to prevent and cure diseases by making high quality stem cells avail...
About 士泽生物医药
士泽生物医药, a promising biopharmaceutical startup founded in 2021, is dedicated to revolutionizing treatments for significant diseases lacking clinical solutions, such as Parkinson's disease. The firm employs scalable, low-cost stem cell therapies, leveraging the potential of human pluripotent stem cells capable of u...
Research and Development, Clinical Trials for CNS diseases, iPSC-derived Drug Development, Technology Platform Innovation
Medical Researchers, Healthcare Providers, Patients with CNS Diseases, Pharmaceutical Companies
Stem Cell Therapy, Degenerative Diseases, IPS Cells, Regenerative Medicine, Cellular Reprogramming, Neurodegenerative Disorders, Gene Editing, Parkinson's Disease, Cell Replacement Therapy, Biotech R&D, Cell Drug Safety, Therapeutic Innovation, Biopharmaceuticals, Translational Research, Cellular Differentiation
B2B, B2C, B2D
Licensing, Service Fee, Performance Based
Frequently Asked Questions
From the desk
Mapping a market? Start with a Rival Readout.
In 7 business days we read 10 rivals around 士泽生物医药: 90 days of dated moves, ranked by what matters to you, each with its source. Fully credited if you continue.
Compiled from the BounceWatch company index. We last looked at 士泽生物医药 on 22 Mar 2026. The 12 companies listed here were last checked between 11 Mar 2026 and 3 Jul 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.